Mayeta Clark 2015

Protective Immunity against Severe Malaria in Children Is Associated with a Limited Repertoire of Antibodies to Conserved PfEMP1 Variants

November 13, 2019

Extreme diversity of the major Plasmodium falciparum antigen, PfEMP1, poses a barrier to identifying targets of immunity to malaria. Here, we used…

Read More

Early and late mortality after malaria in young children in Papua, Indonesia

October 30, 2019

Background In southern Papua, Indonesia, malaria is highly prevalent in young children and is a significant cause of morbidity and…

Read More

Modeling the dynamics of Plasmodium falciparum gametocytes in humans during malaria infection

October 29, 2019

Renewed efforts to eliminate malaria have highlighted the potential to interrupt human-to-mosquito transmission — a process mediated by gametocyte kinetics…

Read More

The efficacy of dihydroartemisininpiperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis

October 4, 2019

Background Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook…

Read More

Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies

August 23, 2019

Background Severe falciparum malaria is a medical emergency characterised by potentially lethal vital organ dysfunction. Patient fatality rates even with…

Read More

The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

August 1, 2019

Background Malaria causes a reduction in haemoglobin that is compounded by primaquine, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency….

Read More

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

July 18, 2019

Background Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day…

Read More

Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study

May 29, 2019

Background Malaria control activities can have a disproportionately greater impact on Plasmodium falciparum than on P. vivax in areas where both species are coendemic. We…

Read More

Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study

May 17, 2019

Background Antimalarial efficacy studies in patients with uncomplicated Plasmodium falciparum are confounded by a new infection (a competing risk event) since this…

Read More

Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia.

April 2, 2019

Background Primaquine (PQ) prevents relapses of vivax malaria but may induce severe haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. Data…

Read More

1 2 3 11